title: Ribosomal P antibody: 30 years on the road.
abstract: The identity of the protein antigens targeted by anti-cytoplasmic antibodies in lupus was discovered 30 years ago. These antigens are three acidic ribosomal phosphoproteins, P0, P1, and P2. Precise identification of the shared epitope on these three proteins enabled sensitive and specific immunoassays to be developed. Anti-P antibodies are highly specific for systemic lupus erythematosus (SLE) and occur in 15%-35% of patients, depending on ethnicity as well as the age of onset. Increased frequencies of detection of anti-P have been reported in childhood SLE as well as in neuropsychiatric, renal, and hepatic disease. While longitudinal studies by the Systemic Lupus International Collaborating Clinics (SLICC) consortium supported the association of anti-P with neuropsychiatric lupus, the predictive value of antibody determination remains controversial. This is likely explained by the heterogeneity of neuropsychiatric lupus as well as by the different methodologies used for assay. A number of experimental studies have suggested a direct pathogenic role for anti-P antibodies in brain disease. Findings include cross reactivity between anti-P and a neuronal surface antigen, which was detected in areas of the brain involved in memory, cognition, and emotion. Direct injection of anti-P antibodies into the brains of rodents was also associated with abnormal electrical activity and behavioral disturbances. Taken together, research over the last 30 years has established anti-P antibodies as a useful diagnostic marker of SLE and at least a subset of patients with neuropsychiatric disease. Further research is required to fine tune the association of anti-P with clinical manifestations and establish beyond high probability a pathophysiologic role for the antibodies.
authors.affiliation: 1 Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil.
authors.forename: V T
authors.initials: VT
authors.lastname: Viana
authors.affiliation: 2 Division of Rheumatology, University of Washington, USA.
authors.forename: L
authors.initials: L
authors.lastname: Durcan
authors.affiliation: 1 Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil.
authors.forename: E
authors.initials: E
authors.lastname: Bonfa
authors.affiliation: 2 Division of Rheumatology, University of Washington, USA.
authors.forename: K B
authors.initials: KB
authors.lastname: Elkon
mesh_terms: D000367:Age Factors; D000818:Animals; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000378:metabolism; D000939:Epitopes / Q000276:immunology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000208:ethnology / Q000276:immunology*; D020945:Lupus Vasculitis, Central Nervous System / Q000208:ethnology / Q000276:immunology; D010750:Phosphoproteins / Q000276:immunology*; D012269:Ribosomal Proteins / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; D000939:Epitopes; D010750:Phosphoproteins; D012269:Ribosomal Proteins
keywords: Lupus; autoantibodies; nephritis; neuropsychiatric